Eliza Slawther
Senior Writer
Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
How Pharma Firms Using AI Should Navigate Regulatory Submissions
Global regulators have yet to develop hard and fast rules for the use of artificial intelligence in drug development. Until they do, pharma companies should be guided by transparency and best practice principles when preparing submissions, a consultant says.
Why Personalized Medicine Poses HTA & Funding Challenges In England
Personalized medicine models could benefit patients, but this approach raises tough economic and prioritization questions for health technology assessment bodies like England’s NICE.
National Real-World Evidence Frameworks For HTA Should Be Consistent, Not Identical
Health technology assessment bodies must strike a fine balance between standardizing their real-world evidence frameworks with those of other countries and tailoring them to meet population-specific needs, an expert tells England’s NICE.
Why Protein Misfolding Diseases Have Been Pharma’s Achilles Heel
Protein misfolding diseases, such as Alzheimer’s, are still largely untreatable and incurable. A leading scientist explains why these diseases pose unique R&D challenges and how researchers are beginning to overcome them.
EU Reaches Last-Minute Agreement On Health Data Space After Tough Negotiations
European co-legislators have reached a compromise on the text of the European Health Data Space that will see the controversial opt-out mechanism included in the framework